Transcatheter arterial chemoembolization and radiation therapy for treatment-naïve patients with locally advanced hepatocellular carcinoma
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim S.W.[Kim S.W.] | - |
dc.contributor.author | Oh D.[Oh D.] | - |
dc.contributor.author | Park H.C.[Park H.C.] | - |
dc.contributor.author | Lim D.H.[Lim D.H.] | - |
dc.contributor.author | Shin S.W.[Shin S.W.] | - |
dc.contributor.author | Cho S.K.[Cho S.K.] | - |
dc.contributor.author | Gwak G.-Y.[Gwak G.-Y.] | - |
dc.contributor.author | Choi M.S.[Choi M.S.] | - |
dc.contributor.author | Paik Y.H.[Paik Y.H.] | - |
dc.contributor.author | Paik S.W.[Paik S.W.] | - |
dc.date.accessioned | 2021-08-04T08:51:38Z | - |
dc.date.available | 2021-08-04T08:51:38Z | - |
dc.date.created | 2016-08-06 | - |
dc.date.issued | 2014 | - |
dc.identifier.issn | 2234-3164 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/skku/handle/2021.sw.skku/58042 | - |
dc.description.abstract | Purpose To evaluate the safety and efficacy of transcatheter arterial chemoembolization (TACE) followed by radiotherapy (RT) in treatment-naïve patients with locally advanced hepatocellular carcinoma (HCC). Materials and Methods Eligibility criteria were as follows: newly diagnosed with HCC, the Barcelona Clinic Liver Cancer stage C, Child-Pugh class A or B, and no prior treatment for HCC. Patients with extrahepatic spread were excluded. A total of 59 patients were retrospectively enrolled. All patients were treated with TACE followed by RT. The time interval between TACE and RT was 2 weeks as per protocol. A median RT dose was 47.25 Gy10 as the biologically effective dose using the α/β = 10 (range, 39 to 65.25 Gy10). Results At 1 month, complete response was obtained in 3 patients (5%), partial response in 27 patients (46%), stable disease in 13 patients (22%), and progressive disease in 16 patients (27%). The actuarial one- and two-year OS rates were 60.1% and 47.2%, respectively. The median OS was 17 months (95% confidence interval, 5.6 to 28.4 months). The median time to progression was 4 months (range, 1 to 35 months). Grade 3 or greater liver enzyme elevation occurred in only two patients (3%) after RT. Grade 3 gastroduodenal toxicity developed in two patients (3%). Conclusion The combination treatment of TACE followed by RT with two-week interval was safe and it showed favorable outcomes in treatment-naïve patients with locally advanced HCC. A prospective randomized trial is needed to validate these results. © 2014. The Korean Society for Radiation Oncology. | - |
dc.subject | alanine aminotransferase | - |
dc.subject | aspartate aminotransferase | - |
dc.subject | doxorubicin | - |
dc.subject | iodinated poppyseed oil | - |
dc.subject | adult | - |
dc.subject | aged | - |
dc.subject | article | - |
dc.subject | cancer growth | - |
dc.subject | cancer survival | - |
dc.subject | chemoembolization | - |
dc.subject | Child Pugh score | - |
dc.subject | disease course | - |
dc.subject | dose response | - |
dc.subject | follow up | - |
dc.subject | four dimensional computed tomography | - |
dc.subject | gastrointestinal toxicity | - |
dc.subject | human | - |
dc.subject | hypertransaminasemia | - |
dc.subject | liver cell carcinoma | - |
dc.subject | major clinical study | - |
dc.subject | overall survival | - |
dc.subject | radiation dose | - |
dc.subject | retrospective study | - |
dc.subject | treatment response | - |
dc.subject | tumor thrombus | - |
dc.subject | tumor volume | - |
dc.title | Transcatheter arterial chemoembolization and radiation therapy for treatment-naïve patients with locally advanced hepatocellular carcinoma | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Oh D.[Oh D.] | - |
dc.contributor.affiliatedAuthor | Park H.C.[Park H.C.] | - |
dc.contributor.affiliatedAuthor | Lim D.H.[Lim D.H.] | - |
dc.contributor.affiliatedAuthor | Shin S.W.[Shin S.W.] | - |
dc.contributor.affiliatedAuthor | Cho S.K.[Cho S.K.] | - |
dc.contributor.affiliatedAuthor | Gwak G.-Y.[Gwak G.-Y.] | - |
dc.contributor.affiliatedAuthor | Choi M.S.[Choi M.S.] | - |
dc.contributor.affiliatedAuthor | Paik Y.H.[Paik Y.H.] | - |
dc.contributor.affiliatedAuthor | Paik S.W.[Paik S.W.] | - |
dc.identifier.doi | 10.3857/roj.2014.32.1.14 | - |
dc.identifier.scopusid | 2-s2.0-84897521086 | - |
dc.identifier.bibliographicCitation | Radiation Oncology Journal, v.32, no.1, pp.14 - 22 | - |
dc.relation.isPartOf | Radiation Oncology Journal | - |
dc.citation.title | Radiation Oncology Journal | - |
dc.citation.volume | 32 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 14 | - |
dc.citation.endPage | 22 | - |
dc.type.rims | ART | - |
dc.description.journalClass | 3 | - |
dc.description.isOpenAccess | Y | - |
dc.subject.keywordAuthor | Hepatocellular carcinoma | - |
dc.subject.keywordAuthor | Radiotherapy | - |
dc.subject.keywordAuthor | Transcatheter arterial chemoembolization | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(03063) 25-2, SUNGKYUNKWAN-RO, JONGNO-GU, SEOUL, KOREAsamsunglib@skku.edu
COPYRIGHT © 2021 SUNGKYUNKWAN UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.